Abstract
Prostacyclin (PGI
2
) is the product of arachidonic acid metabolism generated by the vessel wall of all mammalian species studied, including man. Prostacyclin is a potent vasodilator and the most potent inhibitor of platelet aggregation so far described. Prostacyclin inhibits aggregation through stimulation of platelet adenyl cyclase leading to an increase in platelet cyclic AMP. In the vessel wall, the enzyme that synthesizes prostacyclin is concentrated in the endothelial layer. Prostacyclin can also be a circulating hormone released from the pulmonary circulation. Based on these observations we proposed that platelet aggregability
in vivo
is controlled via a prostacyclin mechanism. The discovery of prostacyclin has given a new insight into arachidonic acid metabolism and has led to a new hypothesis about mechanisms of haemostasis. Reductions in prostacyclin production in several diseases, including atherosclerosis and diabetes, have been described and implicated in the pathophysiology of these diseases. Additionally, since prostacyclin powerfully inhibits platelet aggregation and promotes their disaggregation, this agent could have an important use in the therapy of conditions in which increased platelet aggregation takes place and in which, perhaps, a prostacyclin deficiency exists. Prostacyclin has been used beneficially in humans during extracorporeal circulation procedures such as cardiopulmonary bypass, charcoal haemoperfusion and haemodialysis. Its possible use in other conditions such as peripheral vascular disease or transplant surgery is at present being investigated.
Subject
Industrial and Manufacturing Engineering,General Agricultural and Biological Sciences,General Business, Management and Accounting,Materials Science (miscellaneous),Business and International Management
Reference4 articles.
1. Collier H. O. J. Denning-Kendall P. A. McDonald-Gibson W .J. & Saeed S. A. 1980 Plasma proteins that inhibit prostaglandin synthesis. In Hemostasis prostaglandins and renal disease (ed. G. Remuzzi G. Mecca & G. de Gaetano) pp. 257-267. New York: Raven Press.
2. Collier H. O. J. Denning-Kendall P. A. McDonald-Gibson W. J. Saeed S. A. Brennecke S. P. & Mitchell M. D. 1981 Endogenous inhibitors of prostaglandin synthesis (EIPS) in blood plasma: possible identity and function. In The role of chemical mediators in hemodynamic and metabolicfailure in the critically-ill (ed. R. McConn). New York: Raven Press. (In the press.)
3. Collier H. O. J. & McDonald-Gibson W .J. 1980 Plasma albumin inhibits arachidonate-induced aggregation of suspended platelets. J.Physiol. Lond. (In the press.)
4. Comparison of the inhibition by human serum, haptoglobin and albumin of biosynthesis of various prostaglandins
Cited by
46 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献